Aspects of bone remodeling have only been scarcely studied in X-linked hypophosphatemia (XLH). In this cross-sectional controlled study, we assessed biochemical indices of bone remodeling and sclerostin in 27 adult patients ( ng/ml, p < 0.001). Similar differences were found when comparing currently treated (with phosphate and alfacalcidol) (n = 11) and untreated (n = 16) XLH patients with their respective controls. We found no significant associations with treatment status and indices of bone remodeling or sclerostin although sclerostin tended to be increased in untreated versus treated (p = 0.06). In contrast to previous histomorphometric studies suggesting a low remodeling activity in XLH, these biochemical indices suggest high osteoblast and osteoclast activity. Further studies are needed to ascertain if the higher sclerostin level in XLH is related to osteocyte dysfunction or represents a secondary phenomenon.
Introduction
X-linked hypophosphatemia (XLH) is the most common form of hereditary rickets, caused by a loss of function mutation in the phosphate regulating endopeptidase on the X-chromosome (PHEX) resulting in excess circulating levels of fibroblast growth factor 23 (FGF-23). FGF-23 is a key regulator of phosphate homeostasis and excess levels depress phosphate reabsorption in the kidneys causing hypophosphatemia and, in addition, FGF-23 decreases the synthesis of 1,25 dihydroxyvitamin d. Calcium and phosphorus are the two main minerals composing the non-organic share of bone tissue and sufficient levels of 1,25-dihydroxyvitamin D, as well as phosphate and calcium, are essential for the normal mineralization of bone [1] . In children with XLH the phenotype is characterized by rickets, stunted and disproportionate growth, and lower limb deformities in addition to spontaneous dental abscesses [2] . In adults, the phenotype is dominated by short and disproportionate stature, often persistent bowing of the legs, osteomalacia Electronic supplementary material The online version of this article (https ://doi.org/10.1007/s0022 3-019-00526 -z) contains supplementary material, which is available to authorized users.
and an increasing risk of spontaneous dental abscesses by increasing age [3] .
Studies using bone biopsies and histomorphometry have documented a generalized mineralization defect in both children and adults with XLH with an increased volume of osteoid [4] [5] [6] . Conventional therapy with multiple daily doses of phosphate and calcitriol supplements aim to support bone mineralization and this regimen has shown to diminish metabolic disturbances, improve rachitic lesions, reduce bone deformities, and improve final height in children [7] [8] [9] .
In adult life, after growth completion and fusion of the epiphyses, the skeleton is continuously renewed through bone remodeling; a synchronized process of osteoclastic bone resorption and osteoblastic bone formation with nesting of osteocytes in the newly formed bone. The remodeling process is essential to ensure healing of microfractures and preserve bone strength and for maintaining sufficient levels of minerals in the circulation. It is regulated by both mechanical and metabolic aberrations where the parathyroid-vitamin D axis plays a fundamental role. An increase in bone remodeling rate may alone, or in combination with a net deficit in bone mass with each remodeling cycle, cause a reduction in bone strength and susceptibility to fractures as seen in primary hyperparathyroidism and post-menopausal osteoporosis, respectively. Previous studies of bone metabolism in XLH using bone biopsies have found a reduced bone remodeling rate and a prolonged bone formation period using tetracycline labeling [4, 5] .
Bone remodeling may also be assessed using biochemical markers that serve as indicators of the overall skeletal bone formation and resorption activity of osteoblasts and osteoclasts, respectively. As indicated by Chavassieux et al. [10] biochemical bone remodeling markers are significantly associated with remodeling parameters assessed at the tissue level by bone histomorphometry. Similarly, sclerostin, a protein mainly secreted by osteocytes can be measured as a marker of the osteocytic inhibition of osteoblast bone formation [11] . To what extent these indices are affected in XLH has only been scarcely studied and may be of relevance for a better understanding of the pathophysiology of XLH and since treatment with phosphate and alfacalcidol may be associated with an increase in bone resorption [12] and cortical bone loss [13] .
The aim of this cross-sectional study was to determine bone metabolism, and the potential effects of conventional therapy, using biochemical markers of bone remodeling in patients with XLH compared to healthy control subjects.
Subjects and Methods
Patients included in this study, previously participated in a study in 2006 on the phenotypical presentation of adult patients with XLH [3] . A follow-up examination was performed at Odense University Hospital, Denmark between April 2013 and January 2014 and we have previously presented longitudinal changes in bone mineral density [12] and bone microarchitectural status [13] in patients from this cohort. Of the 38 adult patients participating in the initial study, 27 had the requested blood sampling performed at the follow-up visit and were included in the current study. Recruitment procedures and criteria for inclusion and exclusion have been described earlier [3] . Briefly, a minimum age of 18 years was required for inclusion and patients were verified as having FGF-23 associated hypophosphatemic rickets (HR) either genetically (n = 24) or biochemically by serum PO4 below normal range or low TPO4 /GFR, and elevated serum FGF23 (n = 3). Patients with non-FGF-23 associated HR, sporadic, non-hereditary, or acquired HR were excluded. A disease causing PHEX mutation was found in 15 patients. In nine patients, all included from the same family, a PHEX mutation could not be identified but a genome-wide association linkage scan revealed strong evidence of linkage to the PHEX locus on the X-chromosome. In three patients no mutations could be identified (in PHEX, FGF23, DMP1, SLC34A3, or CLCN5), one of these patients was sporadic and had in addition ENPP1 analyzed where no mutations were identified [14] . Their phenotypical and biochemical characteristics did not differ from the remainder of the participants as previously described [3] .
Eleven patients received conventional medical therapy with alfacalcidol and phosphate and had done so for at least 6 months prior to the examination and were thus considered in steady state. Sixteen patients were treatment naïve although one had been treated sporadically during childhood and was considered treatment naïve.
For each patient with XLH, three sex-and aged-(± 2 years) matched healthy control subjects were included from a previous study of 260 adult women and men participating in a study on age-related changes in bone microarchitecture [15] . For female patients with XLH, additional matching with control subjects was performed with respect to menopausal status (post-menopausal if ≥ 1 year from last menstruation which was accomplished in 53 out of 57 controls) and duration of menopause (± 2 years which was accomplished in all except one post-menopausal patient that was matched ± 5 years).
None of the participants had sustained a fracture in the year preceding blood sampling.
Biochemistry
In patients and controls blood samples were drawn between 8 and 10 am after an overnight fast. Samples for the bone resorption marker carboxyterminal cross-linked telopeptide of type 1 collagen (CTX), the bone formation marker N-terminal propeptide of type 1 procollagen (P1NP), osteocalcin, bone specific alkaline phosphatase (BSALP), and sclerostin were stored at − 80° Celsius until analyses.
CTX was measured using the IDS-iSYS CTX-I (CrossLaps®) assay (Immunodiagnostic Systems, plc, Tyne and Wear, UK) with coefficient of variation (CV)'s of 5.3%, 3.4%, and 3.5% at levels of 213, 869, and 2113 ng/L. P1NP was measured using the IDS-iSYS intact P1NP assay (Immunodiagnostic Systems) with CVs of 5.4%, 6.5%, and 6.1% at levels of 18.96, 48.48, and 122.10 µg/L. Sclerostin was measured using the TECOMedical Sclerostin HS EIA assay (Quidel Corporation, San Diego, CA). Samples were analyzed in duplicate in one batch and according to the manufacturer's instructions. The intra-assay precision was 10% at both 0.2 ng/mL and 1.9 ng/mL levels. Vitamin D was measured using the 25 OH vitamin D total assay on the Liaison XL automated analyzer (Diasorin, Saluggia, Italy) with CV% of 7.2% and 5.2% at levels of 40 and 130 nmol/L, respectively. In XLH patients BSALP was measured using the IDS-iSYS Ostase® BSALP assay (Immunodiagnostic Systems) with CVs of 8.5%, 7.1%, 3.7%, and 6.3% at levels of 4.5, 13.2, 20.1, and 52.1 µg/L, respectively. Osteocalcin was measured using the N-Mid Osteocalcin assay (Immunodiagnostic Systems) with the following CVs: 3.0% (8.73 µg/L), 3.6% (27.6 µg/L), and 3.5% (68.7 µg/L).
Since biochemical screening for disorders of phosphate metabolism was not performed as part of the study from where controls subjects were recruited [15] , we measured creatinine and phosphate in the control subjects to exclude potentially interfering sub-clinical disorders. These analyses revealed normal levels of creatinine and phosphate in every case. Similarly, creatinine, phosphate, ionized calcium, and parathyroid hormone were measured in patients with XLH using routine laboratory assays.
Statistics
We present data as mean ± SD or median [range or IQR] as appropriate. Comparisons between patients with XLH and control subjects were performed using χ 2 test for categorical variables and student T-test or Wilcoxon's rank-sum test for continuous variables depending on distribution of parameters (normal or non-normal distribution, respectively). Similar analyses were performed in subgroups of XLH (and their respective controls) grouped by treatment status. Linear regression analyses were performed to assess correlations of sclerostin and markers of formation and resorption in XLH and controls. To compare values in treated versus non-treated XLH patients a multiple regression analysis was performed controlling for age and sex. Model assumptions were assessed using histograms and quantile-quantile plots of residuals and transformation was performed where required. The p-values were twosided and thus considered significant if below 0.05. All statistical analyses were performed using Stata Statistical Software release 11.0 (StataCorp LP, College Station, TX, USA).
Results
General characteristics of XLH patients and controls are presented in Table 1 . A total of 27 patients with XLH, median age 47 (range 24-79 years), of whom 11 was currently treated with alfacalcidol and phosphate, and 81 controls were included in the study. Patients were shorter (p < 0.001) and had a higher body mass index (p = 0.03) compared to controls.
The resorption marker CTX was higher in XLH patients compared to controls (p < 0.001) and when comparing subgroups of treated XLH patients (p < 0.01) and non-treated XLH patients (p < 0.05) with their respective controls ( Table 2) . A similar pattern was found for the formation marker P1NP with higher levels in XLH patients compared to controls (p < 0.001) and in subgroups of treated (p < 0.001) and non-treated (p < 0.01) XLH patients compared to their respective controls.
Compared to specific reference ranges taking sex and menopausal status into account, patients with XLH had values above upper limit of normal in six of 27 (22%) for CTX, 11 of 27 (41%) for P1NP, 16 of 27 (59%) for BSALP and eight out of 27 (30%) for osteocalcin (Fig. 1) . The Supplementary Table 1 provides the measured bone markers in XLH patients stratified by gender and menopausal status along with established reference ranges.
Sclerostin levels were higher in XLH (p < 0.001) and also in subgroups of treated (p < 0.01) and non-treated (p < 0.01) XLH patients compared to controls. As expected, phosphate was lower in XLH (p < 0.001) and creatinine was similar between groups (p = 0.48) whereas the level of 25-OH vitamin-D3 was lower in controls (p = 0.03). Serum ionized calcium was within reference range in all XLH patients while eight patients (four currently treated) had PTH concentrations above the upper limit of normal (> 6.9 pmol/l) indicative of secondary hyperparathyroidism. None of the XLH patients had tertiary hyperparathyroidism (Table 2) .
There was a significant correlation between serum levels of P1NP and CTX both in XLH (r = 0.70, p < 0.001) and controls (r = 0.88, p < 0.001). There were no significant associations between sclerostin and P1NP or CTX in either XLH patients or controls. When restricted to the group of XLH patients with a PHEX mutation (n = 15) and their respective controls results were similar to those reported for the whole study group.
Effects of Treatment with Phosphate and Alfacalcidol
In the age-and sex-adjusted multiple regression analyses within the XLH group there were no statistically significant difference in CTX (p = 0.18) or P1NP (p = 0.10) while there was a trend for lower sclerostin values in treated versus nontreated XLH patients (p = 0.06) (Fig. 2) .
Discussion
In this study of bone remodeling in adults with XLH using biochemical markers, we found higher indices of both bone formation and resorption activity and higher sclerostin levels in XLH patients compared to age-and sex-matched control subjects. Previous reports of biochemical bone remodeling markers in adults with XLH are limited. Nagata et al. [16] found similar levels of P1NP in nine XLH patients compared with controls while Ros et al. [17] reported elevated P1NP levels in three out of five adults with XLH and elevated CTX in one out of three XLH adults compared to reference values. Zhang et al. [18] measured biochemical markers of bone turnover in adult patients with XLH entering a study of the monoclonal FGF-23 antibody burosomab, and found that, as a group, patients had normal levels of P1NP and CTX compared to reference ranges although they did report that several patients had clearly increased levels. Recently McKenna et al. [19] reported biochemical bone turnover markers in 27 adult patients with congenital hypophosphatemia, where the majority had XLH, and similar to our study, found increased levels of both formation (BSALP, P1NP, and osteocalcin) and resorption (urine NTX and CTX) markers compared to reference ranges.
The bone formation marker P1NP is an N-terminal propeptide of procollagen and is removed by specific proteinases before the collagen molecule forms. As such, in the hierarchy of events occurring during bone formation, it represents a marker of the osteoblastic production of the organic component of bone matrix, an event that occurs in the early stages of bone matrix maturation prior to mineralization. Hypophosphatemic rickets is characterized by defects in the mineralization front rather than a compromised osteoid production as evidenced by histomorphometric studies that have shown greatly increased osteoid surface, volume, and thickness [4] . The finding of higher P1NP therefore presumably reflects an excess production of osteoid. In XLH, P1NP can therefore not be used as a marker of bone formation related to bone remodeling which is supported by the histomorphometric evidence of a reduced bone remodeling rate and a prolonged bone formation period using tetracycline labeling. Tetracycline is given in two courses before the bone biopsy is obtained and forms calcium chelate complexes that bind to bone surfaces. These complexes are buried within newly mineralized bone but will dissociate from other bone surfaces as the serum tetracycline levels decrease, and therefore tetracycline is only incorporated in the mineralized bone and not in osteoid [20] .
Elevation in alkaline phosphatase (ALP) is a biochemical hallmark of osteomalacia and although not assessed in controls in our study, we also found that the majority of XLH patients had elevated levels compared to reference ranges. In bone tissue, ALP is produced by osteoblasts and is vitally involved in the early stages of hard tissue formation where it functions to promote mineralization by decreasing the concentration of the calcification inhibitor inorganic pyrophosphate and increasing the concentration of the mineralization promoter, inorganic phosphate [21] . Osteocalcin is thought to reflect osteoblast activity in the later stages of bone mineralization and was found to be above the upper limit of normal in about one-third of the XLH patients in our study. Theoretically, the increase in ALP and osteocalcin in XLH may represent compensatory mechanisms of excess enzyme activity aiming to mitigate the deficiency of substrate (phosphate) required for bone mineralization. In addition, the defect in mineralization may be related to reduced levels of 1,25-dihydroxyvitamin D [22] and an accumulation of mineralizing-inhibiting peptides such as osteopontin [23] or matrix extracellular phosphoglycoprotein (MEPE) [24] that has been found in XLH patients in relation to PHEX deficiency.
We also found that CTX was increased in XLH patients compared to controls suggesting an increase in bone resorption. Conventional therapy with phosphate and alfacalcidol bears the risk of developing secondary (or even tertiary) hyperparathyroidism causing a PTH mediated increase in bone resorption. Eight patients in our study had mild secondary hyperparathyroidism while only four of these were currently treated with alfacalcidol and phosphate with one untreated XLH patient having mild vitamin D insufficiency (data not shown). We did find that untreated XLH patients had elevated levels of CTX compared to controls although the magnitude of the increase was smaller than in those treated (44% increase in untreated versus 184% increase in treated). There was no statistical significant difference in CTX when comparing XLH patients with and without treatment in the current study. This may due to a lack of statistical power, since we have previously found, in a longitudinal study in the same cohort of XLH patients (that included two values for CTX in each patient) that the overall CTX level was higher in those on treatment and that CTX values increased over the 6 year observation period in those on treatment [12] . Similarly, McKenna et al. [19] found that CTX was higher in those receiving phosphate and alfacalcidol treatment. In untreated children and adults with XLH, histomorphometric studies have reported a normal to increased amount of calcified bone and a normal osteoclastic surface and number [4, 5] and most plausibly the increase in CTX thus primarily represents a consequence of treatment, probably related to increased PTH and to a lesser degree a disease-related phenomenon. In a clinical setting, the use of bone remodeling markers for assessing the degree of osteomalacia is undecided and cannot be clarified from this study given the lack of histomorphometric parameters. However, the sequential monitoring of CTX in addition to PTH, phosphate, and calcium might be of value in individual patients to guide treatment with phosphate and alfacalcidol.
In our study, sclerostin levels were higher in XLH patients compared to controls. Similarly, Palomo et al. [25] found that sclerostin levels were 39% higher in a cohort of children and adults with XLH patients compared to controls and this increase was irrespective of treatment with phosphate and alfacalcidol. The mechanism responsible for the increase in sclerostin in XLH is unknown. HYP mice that are murine homologs of XLH with a similar phenotype of hypophosphatemia, increased FGF-23, renal phosphate wasting and rickets/osteomalacia also have increased sclerostin in the circulation [26] as well as increased Sost mRNA expression (the gene coding for sclerostin) in the long bones [27] . On the contrary, mice with an inactivating mutation in Sost present with a phenotype of skeletal overgrowth and sclerostosis but also have decreased FGF-23, increased levels of phosphate and increased 1,25-dihydroxyvitamin D compared to wildtype mice [28] . Thus apart from regulating osteoblastic bone formation sclerostin also regulates mineral homeostasis of phosphate and calcium. Speculatively, the increased sclerostin in XLH may thus be a compensatory phenomenon aiming to mitigate the excess FGF-23 and hypophosphatemia.
It is possible to interpret our findings of higher bone formation and resorption indices in the framework of the mechanostat model. According to this model, bone metabolism (longitudinal growth, bone modeling, and remodeling activities) in load bearing bones adapts in relation to mechanical usage and muscle forces in a manner that keeps typical peak voluntary mechanical loads from causing nontraumatic fractures [29] . Thus, for a given force level, the persistent mineralization defect in XLH would, in theory, lead to greater bone metabolism, bone deformity, and consequently larger bone size than normally mineralized bone. In line with this interpretation, we [13] , as well as other authors [30] have previously shown that patients with XLH have larger bone size than age-and sex-matched healthy controls.
There are some limitations to our study. We had a limited sample size that precludes the assessment of sex-and agespecific associations and likely also a firm evaluation of the effects of treatment. Moreover, bone biopsies were not available which precluded a direct comparison of biochemical and histomorphometric remodeling parameters. The degradation and clearance of collagen propeptides is completed through a scavenger system where intact trimers of propeptides are eliminated through the liver and monomers are cleared through the kidneys [31, 32] . CTX is mainly cleared through the kidneys with some additional hepatic degradation [33] . Whether the clearance of P1NP or CTX from the circulation is reduced in patients with XLH is unknown but is likely of less importance in our study, where all participants had normal renal function and no known hepatic disease. Although XLH is a systemic disease, focal skeletal phenomena are also commonly observed, in particular the appearance of Looser zones that are considered as a type of insufficiency fracture [34] . The occurrence of a regular fracture leads to a marked increase in bone turnover markers and whether there is a focal increase in bone formation and/or resorption in areas with Looser zones is unknown but this may potentially compromise the use of bone turnover markers as indicators of overall skeletal remodeling in XLH.
An important strength of this study was the inclusion of a homogeneous group of adult patients with X-linked dominantly inherited disease and a distinct clinical and biochemical phenotype where the disease-specific genetic defect was verified in the majority of patients. Also we included a control group comprising population-based subjects matched for age-, sex-, and menopausal status in order to limit confounding effects.
In conclusion, we found that patients with XLH had higher levels of biochemical markers of bone resorption and formation suggesting an increase in both osteoclast activity and osteoblast osteoid formation compared to ageand sex-matched control subjects along with an increase in sclerostin, which may represent osteocyte dysfunction or a compensatory phenomenon. There were no significant effects of treatment with phosphate and alfacalcidol on bone markers and their potential use in clinical care in patients with XLH seems low.
